Drug cost escalation isn't resolved by imposing price restrictions.
In a bold move, the Trump administration has issued an executive order on May 12, aiming to take aggressive action against high-charging drug firms. The order directs the Department of Health and Human Services (HHS) to communicate the administration's desire for most-favored-nation (MFN) pricing in the United States.
The move is part of a broader strategy to address the issue of high prescription drug prices, with some claiming that Washington should impose price controls to ensure affordable access. However, it's important to note that the administration's approach is not limited to price controls, but also includes the threat of tariffs and encouraging reshoring of production.
The executive order targets pharmaceutical companies broadly, but no specific companies have been explicitly named as targets. If companies don't make "significificant progress" toward the goal of MFN pricing, the order directs HHS to propose regulations to impose the pricing.
However, the HHS may not have the statutory authority to impose price controls, particularly in private markets outside of Medicare, Medicaid, and CHIP. The administration's previous attempt to impose MFN-style price caps was struck down in the courts due to noncompliance with notice-and-comment rules.
The high prices of prescription drugs in the U.S. are a matter of concern, with U.S. prices for branded drugs being at least 3.22 times higher than those of comparable developed countries. This discrepancy is due to a combination of domestic policies and agreements between drug manufacturers, private payers, and pharmacy benefit managers.
One such agreement can result in higher out-of-pocket costs for consumers, with higher premiums and copays to make up for price reductions. The executive order directs drug manufacturers to align U.S. prices with the lowest offered in "comparably developed nations."
The pharmaceutical industry could respond to the president's order in several ways to mitigate the impact. They could limit supply or manipulate prices in foreign countries, pursue U.S.-only drug launches, or adjust rebate agreements with middlemen.
It's worth noting that studies show that companies need to price their products to recoup R&D investments. America, with less than five percent of the world's population, yet generates roughly 75% of global pharmaceutical profits. President Trump explained that he intended not to reduce overall pharma revenues but to ensure each country pays its fair share.
Bringing a single medication to market costs between $880 million and $2.2 billion. A hypothetical cancer drug might be priced at $300 per dose in America to recover costs over the drug's patent.
The White House hopes the order will cause other countries to raise prices, responding to drug-company pressure. This could potentially lead to a more equitable distribution of drug costs across the globe. The discussions with drug manufacturers and European leaders include the possibility of lifting prices in Europe and elsewhere, and Pfizer CEO Albert Bourla has floated the idea of a NATO-like alliance to distribute the cost-burden of innovation more fairly.
As the situation develops, it will be interesting to see how the pharmaceutical industry responds and how the executive order impacts drug prices in the U.S. and globally.
Read also:
- Understanding Hemorrhagic Gastroenteritis: Key Facts
- Stopping Osteoporosis Treatment: Timeline Considerations
- Tobacco industry's suggested changes on a legislative modification are disregarded by health journalists
- Expanded Community Health Involvement by CK Birla Hospitals, Jaipur, Maintained Through Consistent Outreach Programs Across Rajasthan
